Samsung Life Insurance (A032830) Q1 2026 earnings summary
Event summary combining transcript, slides, and related documents.
Q1 2026 earnings summary
14 May, 2026Executive summary
Net income for Q1 2026 surged 89.5% YoY to KRW 1,203.6 billion, driven by stable insurance earnings, higher dividend income, and increased equity method and consolidated earnings from subsidiaries and associates.
Net profit for 1Q FY26 surged 90% year-over-year, driven by stable insurance profit and a significant increase in investment profits.
New business CSM increased 11% QoQ to KRW 848.6 billion, with balanced growth across exclusive and non-exclusive channels.
CSM balance reached KRW 13.6 trillion, up KRW 0.4 trillion YTD, supported by solid new business and stable insurance efficiency management.
Shareholders' equity increased by W18.5 tn year-to-date, supported by robust profit generation and higher SEC share price.
Financial highlights
1Q FY26 consolidated net profit was W1.2 tn, with W257 bn from insurance service results and W1.3 tn from investment profits.
Investment profits rose 125.5% year-over-year, mainly from dividend income and subsidiary contributions.
Loss ratio maintained at 85%, in line with business plan.
K-ICS ratio stood at 210% at Q1 end, up 12 percentage points from year end, reflecting growth in CSM, earnings expansion, and favorable equity and interest rate movements.
Dividend per share (DPS) has grown by more than 16% annually over the last five years.
Outlook and guidance
Commitment to stable and sustainable dividend growth per share, with a mid- to long-term payout target of 50%.
Open to spreading out special dividend distributions over multiple years if large-scale non-recurring profits are realized.
Focus on enhancing corporate value through higher dividends and improved operating ROE.
Continued focus on disciplined ALM management and strategic asset allocation amid changing macroeconomic and geopolitical conditions.
Latest events from Samsung Life Insurance
- FY2025 net profit rose 9.3% to KRW 2.3T, with record CSM and DPS up 18%; strong 2026 growth targeted.A032830
Q4 202512 Apr 2026 - Net profit up 40.5% YoY to KRW 1,369bn, led by health segment and investment gains.A032830
Q2 20242 Feb 2026 - Q3 net profit up 41.6% YoY, led by health insurance and investment growth.A032830
Q3 202413 Jan 2026 - Record profit, robust capital, and higher dividends driven by health segment growth.A032830
Q4 20248 Jan 2026 - Net profit up 2.1% YoY to ₩635.3bn, health CSM at record high, K-ICS ratio stable at 180%.A032830
Q1 202527 Dec 2025 - H1 2025 net profit up 1.9% to KRW 1.394T, with improved CSM, KICS, and ESG rating AA.A032830
Q2 202523 Nov 2025 - Net profit up 3.7% YoY, with strong capital, robust health CSM, and higher equity.A032830
Q3 202513 Nov 2025